The Trustees of the University of Pennsylvania, through its Clinical Practices, received a $530,697 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for the treatment of high-grade serous ovarian cancer and triple-negative breast cancer. The overarching objective is to systematically explore the mechanisms of action and therapeutic potential of PRMT inhibitor mono- and combination therapies in these cancer types. The 5-year project, starting August 2024, aims to characterize the molecular mechanisms of PRMT inhibitor treatments, evaluate their therapeutic efficacy in preclinical models, and investigate their effects on anti-tumor immune responses. This research is expected to provide critical insights to enable the clinical development of PRMT inhibitors for oncology applications.
Generated 3/4/25, 6:59 AM